STRATEGY
COMBINING SAFETY AND EFFICIENCY IN RECONSTITUTED DRUGS IN THE FAR EAST MARKETS Can advanced dual-chamber solutions help?
L
The article focuses on the peculiarities of the Chinese pharmaceutical market, characterized by high growth rates. In particular, reconstituted drugs are one of the highest growth market segments, with the increasingly growing need of dedicated solutions to protect drugs from moisture, which Bormioli Pharma has addressed presenting cutting-edge, advanced solutions. Valiant Chen, China Sales Manager, Bormioli Pharma
20
P H A RM A F O C U S A S I A
ISSUE 44 - 2021
atest figures show that China is the second pharmaceutical market in the world after the United States, with an overall value amounting to about 103 billion dollars in 2020. A further leap forward is expected for 2021, with estimates forecasting Chinese pharmaceutical market to outperform the global market both in the short term (+13 per cent) and in the long term with a +5.6 per cent compound annual growth rate compared to the global value of +5 per cent. Latest estimates also show that China is likely to become the first pharmaceutical market in the world in 10 years, even though the figures show that the market has still a lot of consolidation to do before surpassing the United States, that now accounts for 40.4 per cent of the total revenues worldwide, compared to 11 per cent of China. Indeed, demand for healthcare services and products in China continues to grow, alongside the government’s effort to advance the sector’s development with increased investments – up to 8 per cent of the domestic GDP in 2026, compared to 6.5 per cent registered in 2020 - in related infrastructure, pharmaceutical research, medical
